B-intervention	0	9	Endocrine
I-intervention	10	17	therapy
I-intervention	18	22	with
I-intervention	23	25	or
I-intervention	26	33	without
I-intervention	34	39	whole
I-intervention	40	46	breast
I-intervention	47	58	irradiation
O	59	61	in
O	62	65	low
O	65	66	-
O	66	70	risk
O	71	77	breast
O	78	84	cancer
O	85	93	patients
O	94	99	after
O	100	106	breast
O	106	107	-
O	107	117	conserving
O	118	125	surgery
O	125	126	:
O	127	129	10
O	129	130	-
O	130	134	year
O	135	142	results
O	143	145	of
O	146	149	the
O	150	158	Austrian
O	159	165	Breast
O	166	169	and
O	170	180	Colorectal
O	181	187	Cancer
O	188	193	Study
O	194	199	Group
O	200	202	8A
O	203	208	trial
O	208	209	.

O	210	212	To
O	213	224	investigate
O	225	229	long
O	229	230	-
O	230	234	term
O	235	242	results
O	243	245	of
O	246	254	patients
O	255	259	with
O	260	268	hormonal
O	269	277	receptor
O	277	278	-
O	278	286	positive
O	287	293	breast
O	294	300	cancer
O	301	308	treated
O	309	313	with
O	314	320	breast
O	320	321	-
O	321	331	conserving
O	332	339	surgery
O	340	341	(
O	341	344	BCS
O	344	345	)
O	346	349	and
O	350	361	consecutive
O	362	371	endocrine
O	372	379	therapy
O	380	381	(
O	381	383	ET
O	383	384	)
O	385	389	with
O	390	392	or
O	393	400	without
O	401	406	whole
O	407	413	breast
O	414	425	irradiation
O	426	427	(
O	427	430	WBI
O	430	431	)
O	431	432	.

O	433	439	Within
O	440	443	the
O	444	445	8
O	446	447	A
O	448	453	trial
O	454	456	of
O	457	460	the
B-location	461	469	Austrian
O	470	476	Breast
O	477	480	and
O	481	491	Colorectal
O	492	498	Cancer
O	499	504	Study
O	505	510	Group
O	510	511	,
O	512	513	a
O	514	519	total
O	520	522	of
B-total-participants	523	526	869
O	527	535	patients
O	536	544	received
O	545	547	ET
O	548	553	after
O	554	557	BCS
O	558	563	which
O	564	567	was
O	568	576	randomly
O	577	585	followed
O	586	588	by
O	589	592	WBI
O	593	594	(
O	594	595	n
O	596	597	=
B-intervention-participants	598	601	439
O	601	602	,
O	603	608	group
O	609	610	1
O	610	611	)
O	612	614	or
B-control	615	626	observation
O	627	628	(
O	628	629	n
O	630	631	=
B-control-participants	632	635	430
O	635	636	,
O	637	642	group
O	643	644	2
O	644	645	)
O	645	646	.

O	647	650	WBI
O	651	654	was
O	655	662	applied
O	663	665	up
O	666	668	to
O	669	670	a
O	671	675	mean
O	676	681	total
O	682	688	dosage
O	689	691	of
O	692	694	50
O	695	697	Gy
O	698	699	(
O	699	700	+
O	700	701	/
O	701	702	-
O	703	705	10
O	706	708	Gy
O	709	714	boost
O	714	715	)
O	716	718	in
O	719	731	conventional
O	732	745	fractionation
O	745	746	.

O	747	752	After
O	753	754	a
O	755	761	median
O	762	768	follow
O	768	769	-
O	769	771	up
O	772	774	of
O	775	776	9
O	776	777	.
O	777	779	89
O	780	785	years
O	785	786	,
B-iv-bin-abs	787	789	10
B-outcome	790	792	in
I-outcome	792	793	-
I-outcome	793	799	breast
I-outcome	800	811	recurrences
I-outcome	812	813	(
I-outcome	813	817	IBRs
I-outcome	817	818	)
O	819	823	were
O	824	832	observed
O	833	835	in
O	836	841	group
O	842	843	1
O	844	847	and
B-cv-bin-abs	848	850	31
O	851	853	in
O	854	859	group
O	860	861	2
O	861	862	,
O	863	872	resulting
O	873	875	in
O	876	877	a
B-outcome	878	880	10
I-outcome	880	881	-
I-outcome	881	885	year
I-outcome	886	891	local
I-outcome	892	902	recurrence
I-outcome	902	903	-
I-outcome	903	907	free
I-outcome	908	916	survival
I-outcome	917	918	(
I-outcome	918	922	LRFS
I-outcome	922	923	)
O	924	926	of
B-iv-bin-percent	927	929	97
I-iv-bin-percent	929	930	.
I-iv-bin-percent	930	931	5
I-iv-bin-percent	931	932	%
O	933	936	and
B-cv-bin-percent	937	939	92
I-cv-bin-percent	939	940	.
I-cv-bin-percent	940	941	4
I-cv-bin-percent	941	942	%
O	942	943	,
O	944	956	respectively
O	957	958	(
O	958	959	p
O	960	961	=
O	962	963	0
O	963	964	.
O	964	967	004
O	967	968	)
O	968	969	.

O	970	974	This
O	975	985	translated
O	986	990	into
O	991	1004	significantly
O	1005	1011	higher
B-outcome	1012	1017	rates
I-outcome	1018	1021	for
I-outcome	1022	1029	disease
I-outcome	1029	1030	-
I-outcome	1030	1034	free
I-outcome	1035	1043	survival
I-outcome	1044	1045	(
I-outcome	1045	1048	DFS
I-outcome	1048	1049	)
O	1049	1050	:
B-iv-bin-percent	1051	1053	94
I-iv-bin-percent	1053	1054	.
I-iv-bin-percent	1054	1055	5
I-iv-bin-percent	1055	1056	%
O	1057	1062	group
O	1063	1064	1
O	1065	1067	vs
B-cv-bin-percent	1068	1070	88
I-cv-bin-percent	1070	1071	.
I-cv-bin-percent	1071	1072	4
I-cv-bin-percent	1072	1073	%
O	1074	1079	group
O	1080	1081	2
O	1081	1082	,
O	1083	1084	p
O	1085	1086	=
O	1087	1088	0
O	1088	1089	.
O	1089	1093	0156
O	1093	1094	.

O	1095	1098	For
B-outcome	1099	1106	distant
I-outcome	1107	1117	metastases
I-outcome	1117	1118	-
I-outcome	1118	1122	free
I-outcome	1123	1131	survival
I-outcome	1132	1133	(
I-outcome	1133	1137	DMFS
I-outcome	1137	1138	)
O	1139	1142	and
B-outcome	1143	1150	overall
I-outcome	1151	1159	survival
I-outcome	1160	1161	(
I-outcome	1161	1163	OS
I-outcome	1163	1164	)
O	1164	1165	,
O	1166	1176	respective
O	1177	1179	10
O	1179	1180	-
O	1180	1184	year
O	1185	1190	rates
O	1191	1199	amounted
B-iv-bin-percent	1200	1202	96
I-iv-bin-percent	1202	1203	.
I-iv-bin-percent	1203	1204	7
I-iv-bin-percent	1204	1205	%
O	1206	1209	and
B-iv-bin-percent	1210	1212	86
I-iv-bin-percent	1212	1213	.
I-iv-bin-percent	1213	1214	6
I-iv-bin-percent	1214	1215	%
O	1216	1219	for
O	1220	1225	group
O	1226	1227	1
O	1228	1234	versus
B-cv-bin-percent	1235	1237	96
I-cv-bin-percent	1237	1238	.
I-cv-bin-percent	1238	1239	4
I-cv-bin-percent	1239	1240	%
O	1241	1244	and
B-cv-bin-percent	1245	1247	87
I-cv-bin-percent	1247	1248	.
I-cv-bin-percent	1248	1249	6
I-cv-bin-percent	1249	1250	%
O	1250	1251	,
O	1252	1255	for
O	1256	1261	group
O	1262	1263	2
O	1264	1265	(
O	1265	1267	ns
O	1267	1268	)
O	1268	1269	.

B-outcome	1270	1273	WBI
O	1274	1275	(
O	1275	1281	hazard
O	1282	1287	ratio
O	1288	1289	[
O	1289	1291	HR
O	1291	1292	]
O	1292	1293	:
O	1294	1295	0
O	1295	1296	.
O	1296	1298	27
O	1298	1299	,
O	1300	1301	p
O	1302	1303	<
O	1304	1305	0
O	1305	1306	.
O	1306	1308	01
O	1308	1309	)
O	1310	1313	and
B-outcome	1314	1320	tumour
I-outcome	1321	1328	grading
O	1329	1330	(
O	1330	1332	HR
O	1332	1333	:
O	1334	1335	3
O	1335	1336	.
O	1336	1338	76
O	1338	1339	,
O	1340	1341	p
O	1342	1343	=
O	1344	1345	0
O	1345	1346	.
O	1346	1348	03
O	1348	1349	)
O	1350	1354	were
O	1355	1360	found
O	1361	1363	as
O	1364	1375	significant
O	1376	1386	predictors
O	1387	1390	for
O	1391	1394	IBR
O	1395	1397	in
O	1398	1406	multiple
O	1407	1410	cox
O	1411	1421	regression
O	1422	1430	analysis
O	1430	1431	.

O	1432	1437	After
O	1438	1439	a
O	1440	1446	median
O	1447	1453	follow
O	1453	1454	-
O	1454	1456	up
O	1457	1459	of
O	1460	1462	10
O	1463	1468	years
O	1468	1469	,
O	1470	1473	WBI
O	1474	1482	resulted
O	1483	1485	in
O	1486	1487	a
O	1488	1494	better
B-outcome	1495	1500	local
I-outcome	1501	1508	control
O	1509	1512	and
B-outcome	1513	1516	DFS
O	1517	1525	compared
O	1526	1530	with
O	1531	1533	ET
O	1534	1539	alone
O	1539	1540	.

O	1541	1544	The
O	1545	1553	omission
O	1554	1556	of
O	1557	1560	WBI
O	1561	1564	and
O	1565	1571	tumour
O	1572	1579	grading
O	1579	1580	,
O	1581	1593	respectively
O	1593	1594	,
O	1595	1599	were
O	1600	1603	the
O	1604	1608	only
O	1609	1617	negative
O	1618	1628	predictors
O	1629	1632	for
O	1633	1637	LRFS
O	1637	1638	.
